Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities-a commentary of the 3-year follow-up of the KEYNOTE-001 trial.

Transl Cancer Res · 2019 · PMC8797642 · PMID 35117140

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

SD), with a favorable trend in OS (HR 0.63).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.